BST Position Update – October 16, 2015
. . . . Anthera Pharmacuticals (NASDAQ: $ANTH) – Buy
Anthera currently has three drugs that are in the clinical stage of research, SOLUTION, Chablis-SC, and Bright-SC.
Anthera recently announced that they have regained worldwide rights to the drug, Blisibimod, which is being tested in the Chablis-SC study, after ending a partnership with Zanyaku, a Japanese company.
Last trade alert, I recommended buying the stock and already it has gone up 10% in one week!
If you haven’t yet bought ANTH, there is still time to purchase. My recommended buy up to price is $7.00 and the stock is currently trading at $6.70.
Invest in this well performing biotech stock while you still can.
. . . . OncoMed Pharmaceuticals (NASDAQ: $OMED) – Hold
I recommended this biotech stock last month and it is on fire!
The current price is $19.32, which is up 27% from our buy price!
The recently company announced that they have completed enrollment of Phase 2 Apline Clinical Trials of Tarextumab 8 months ahead of schedule.
There is a high probability this company will see profits very soon, with seven products currently in clinical trial.
Hold onto OMED as the stock has reached our recommend buy up to price of $17.00.
Action To Take
- Buy ANTH
- Hold OMED
Category: BST Update
